ABSTRACT
Background: Patients diagnosed with influenza and upper respiratory tract infections (URTIs) have similar clinical manifestations and biochemical indices and a low detection rate of viral pathogens, mixed infection with diverse respiratory viruses, and targeted antiviral treatment difficulty in the early stage. According to the treatment strategy of "homotherapy for heteropathy" in traditional Chinese medicine (TCM), different diseases with the same clinical symptoms can be treated with the same medicines. Qingfei Dayuan granules (QFDY), a type of Chinese herbal preparation included in the TCM Diagnosis and Treatment Protocol for COVID-19 of Hubei Province issued by the Health Commission of Hubei Province in 2021, are recommended for patients suffering from COVID-19 with symptoms of fever, cough, and fatigue, among others. Additionally, recent studies have shown that QFDY effectively alleviates fever, cough, and other clinical symptoms in patients with influenza and URTIs. Materials and methods: The study was designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial for treatment for influenza and URTIs manifested by pulmonary heat-toxin syndrome (PHTS) with QFDY. A total of 220 eligible patients were enrolled from eight first-class hospitals in five cities of Hubei Province in China and randomly assigned to receive either 15 g of QFDY or a placebo three times a day for 5 days. The primary outcome was the complete fever relief time. Secondary outcomes included efficacy evaluation of TCM syndromes, scores of TCM syndromes, cure rate of each single symptom, incidence of comorbidities and progression to severe conditions, combined medications, and laboratory tests. Safety evaluations mainly involved adverse events (AEs) and changes in vital signs during the study. Results: Compared with the placebo group, the complete fever relief time was shorter in the QFDY group, 24 h (12.0, 48.0) in the full analysis set (FAS) and 24 h (12.0, 49.5) in the per-protocol set (PPS) (p ≤ 0.001). After a 3-day treatment, the clinical recovery rate (22.3% in the FAS and 21.6% in the PPS) and cure rate of cough (38.6% in the FAS and 37.9% in the PPS), a stuffy and running nose, and sneezing (60.0% in the FAS and 59.5% in the PPS) in the QFDY group were higher than those in the placebo group (p < 0.05). The number of patients taking antibiotics for more than 24 h in the placebo group (nine cases) was significantly higher than that in the QFDY group (one case) (p < 0.05). There were no significant differences between the two groups in terms of scores of TCM syndromes, incidence of comorbidities or progression to severe conditions, combined use of acetaminophen tablets or phlegm-resolving medicines, and laboratory tests (p > 0.05). Meanwhile, no significant difference was found in the incidence of AEs and vital signs between the two groups (p > 0.05). Conclusion: The trial showed that QFDY was an effective and safe treatment modality for influenza and URTIs manifested by PHTS because it shortened the complete fever relief time, accelerated clinical recovery, and alleviated symptoms such as cough, a stuffy and running nose, and sneezing during the course of treatment. Clinical trial registration: https://www.chictr.org.cn/showproj.aspx?proj=131702, identifier ChiCTR2100049695.
ABSTRACT
BACKGROUND: Antarctic krill oil (KO) is a natural source of n-3 polyunsaturated fatty acids (n-3 PUFAs), and is rich in phospholipids, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA), astaxanthin, flavonoids, vitamins, trace elements, and other bioactive substances. KO has been confirmed to have anti-inflammatory and immunomodulatory effects. n-3 PUFAs also have been purported to improve the recovery of muscular performance. Moreover, the phospholipids present in KO can enhance n-3 PUFA bioavailability because of its higher absorption rate in plasma compared to fish oil. Astaxanthin, found in Antarctic KO, is a red carotenoid and powerful antioxidant that inhibits oxidative stress after intense exercise. Hence, we examined the effect of KO supplementation on the recovery of exercise by measuring muscular performance, oxidant/antioxidant and anti-inflammatory activity, and the markers of muscle damage following a rigorous bout of resistance exercise. METHODS: 30 college-aged resistance-trained males (20.4 ± 0.92 years, 74.09 ± 7.23 kg, 180.13 ± 4.72 cm) were randomly supplemented with 3 g/d KO or placebo (PL) for 3 days and continued to consume after resistance exercise for 3 days until the experiment finished. Before supplementation, pre-exercise performance assessments of knee isokinetic strength, 20 m sprint, hexagon test, and blood serum creatine kinase (CK), lactate dehydrogenase (LDH), superoxide dismutase (SOD), total antioxidant capacity (T-AOC), reactive oxygen species (ROS), malondialdehyde (MDA), interleukin-2 (IL-2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were completed. Then after 3 days of supplementation, participants completed a bout of muscle-damaging exercise, and subsequently, they performed and repeated the exercise performance assessments and blood-related indicators tests immediately (0 h), as well as at 6, 24, 48, and 72 h post-muscle-damaging exercise. RESULTS: Compared to the PL group, the serum CK of KO group was significantly lower at 24 h and 48 h post-exercise; the hexagon test time of the KO group was significantly lower than that of the PL group at 6 h and 24 h post-exercise; the KO group's isokinetic muscle strength showed different degrees of recovery than that of the PL group at 24 h and 48 h, and even over-recovery at 72 h post-exercise; the SOD level of the KO group was significantly higher than that of the PL group at 0, 6, and 24 h after exercise; the T-AOC level of the KO group was significantly higher than that of the PL group at 0, 6, and 72 h after exercise; the MDA level of the KO group was significantly lower than that of the PL group at 6 h; and there was no significant difference in serum IL-2, IL-6, and TNF-α between the two groups. CONCLUSION: Our results demonstrated that 3 g/d KO supplementation and continued supplementation after exercise can alleviate exercise-induced muscle damage (EIMD) and promote post-exercise recovery.
Subject(s)
Euphausiacea , Fatty Acids, Omega-3 , Resistance Training , Animals , Humans , Male , Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Dietary Supplements , Fatty Acids, Omega-3/pharmacology , Interleukin-2/pharmacology , Interleukin-6 , Muscle, Skeletal , Phospholipids , Superoxide Dismutase , Tumor Necrosis Factor-alphaABSTRACT
The quality of pork, such as intramuscular fat (IMF) content and flavor, can affect the acceptance of the consumer. Many studies have reported on the pork quality of Chinese local and commercial pigs (for example Large White (LW) pigs). The Jianhe White Xiang (JWX) pig, one of the Chinese Xiang pigs, is known for its high IMF and pork flavor. However, studies investigating the characterization and difference of lipids and metabolites between the JWX and LW pork are limited. Herein, we performed metabolomic and lipidomic profiling of JWX and LW pork by high-performance liquid chromatography-tandem mass spectrometry. The IMF and meat redness (a*) of the JWX pork were significantly higher than those of the LW pork. Metabolomic profiling revealed that 118 out of 501 polar metabolites, such as carnitine, amino acids, sugar, and dipeptide, were significantly different between the two types of pork. Additionally, the screened metabolites were mainly related to carnitine synthesis, phospholipid metabolism, sugar metabolism, and amino acid metabolism. Lipidomic profiling identified 100 of 376 lipids, which contained carnitine, diglyceride, triglyceride (TG), sphingomyelin, cardiolipin, fatty acid, phosphatidylcholine (PC), and phosphatidylethanolamine (PE), which were significantly different between the two types of pork under the positive and negative ion modes (variable importance in projection (VIP) > 1, p < 0.05, and fold change (FC) > 2 or FC < 0.5). All of the different TG substances were up-regulated in the JWX pork, and their carbon chain length was longer than that of the residual TGs. In addition, the JWX pork had more double bonds of PC and PE substances than LW pork. Thus, our findings provide comprehensive metabolomic and lipidomic profiles between the JWX and LW pork and a basic understanding on increasing the pork quality.
Subject(s)
Pork Meat , Red Meat , Swine , Animals , Chromatography, High Pressure Liquid , Tandem Mass Spectrometry , Carnitine , Lecithins , Triglycerides , SugarsABSTRACT
OBJECTIVE: To explore the clinical efficacy of focused extracorporeal shock wave therapy with centrifugal exercise in the treatment of greater trochanteric pain syndrome. METHODS: From September 2017 to June 2019, 53 eligible cases of greater trochanteric pain syndrome were randomly divided into observation group (29 cases) and control group (24 cases). In observation group, there were 8 males and 21 females, aged from 38 to 62 years old with an average of (49.96±6.39) years old; the course of disease ranged from 6 to 13 months with an average of (8.58±1.99) months;treated with focused extracorporeal shock wave therapy with centrifugal exercise. In control group, there were 5 males and 19 females, aged from 39 to 62 years old with an average of (52.79±5.86) years old;the course of disease ranged from 6 to 14 months with an average of (9.04±2.51) months;treated with centrifugal exercise alone. Visual analogue scale (VAS) and hip Harris score were measured before ESWT treatment and at 1, 2, and 6 months to evaluate relieve degree of pain and functional recovery of hip joint, respectively. RESULTS: At 1 month after treatment, there were no significant differences in VAS, hip Harris score and treatment success rate (all P>0.05). At 2 months after treatment, VAS score in observation group (3.20±0.81) was lower than that of control group (3.87±0.61, P=0.002), there were no significant differences in hip Harris score score between observation group (81.93±2.43) and control group (82.12±2.34, P=0.770), the treatment success rate in observation group (58.62%, 17 / 29) was higher than that of control group (29.16%, 7 / 24) (P=0.032). At 6 months after treatment, VAS score in observationgroup (2.24±0.68) was lower than that of control group (3.12±0.53, P<0.001), hip Harris score score in observation group(85.10±1.75) was higher than that of control group (83.66±1.78)(P=0.005), there were no significant differences in treatment success rate between observation group (82.75%, 24 / 29) and control group (62.50%, 15 / 24)(P=0.096). CONCLUSION: In treatment of greater trochanteric pain syndrome, focused extracorporeal shock wave therapy with centrifugal exercise could significantly relieve symptoms of lateral hip pain, improve functional recovery of hip joint with good safety. This treatment strategy is worthy of application and promotion in clinical practice.
Subject(s)
Bursitis , Extracorporeal Shockwave Therapy , Adult , Arthralgia , Female , Hip , Hip Joint , Humans , Male , Middle Aged , Treatment OutcomeABSTRACT
OBJECTIVE: We aimed to evaluate the safety and efficacy of intra-articular (IA) magnesium (Mg) for postoperative pain relief after arthroscopic knee surgery. METHODS: We searched PubMed, Embase, Medline, Cochrane library, and Web of Science to identify randomized controlled trials that compared postoperative pain outcomes with or without IA Mg after knee arthroscopy. The primary outcomes were pain intensity at rest and with movement at different postoperative time points and cumulative opioid consumption within 24 h after surgery. Secondary outcomes included the time to first analgesic request and side effects. RESULTS: In total, 11 studies involving 677 participants met the eligibility criteria. Pain scores at rest and with movement 2, 4, 12, and 24 h after surgery were significantly lower, doses of supplementary opioid consumption were smaller, and the time to first analgesic requirement was longer in the IA Mg group compared with the control group. No significant difference was detected regarding adverse reactions between the groups. CONCLUSIONS: Intra-articular magnesium is an effective and safe coadjuvant treatment for relieving postoperative pain intensity after arthroscopic knee surgery. Protocol registration at PROSPERO: CRD42020156403.
Subject(s)
Arthroscopy/adverse effects , Knee Joint/surgery , Magnesium/administration & dosage , Pain Management/methods , Pain, Postoperative/drug therapy , Randomized Controlled Trials as Topic , Adult , Female , Humans , Injections, Intra-Arterial , Male , Middle Aged , Pain, Postoperative/etiology , Time Factors , Treatment Outcome , Young AdultABSTRACT
Natural zeolite has been recognized as a useful adsorbent for wastewater treatment for removing cations. Natural zeolite is a kind of porous material with large specific surface area but limited adsorption capacity. In recent years, emphasis has been given to prepare the surface modified zeolite using various procedures to enhance the potential of zeolite for pollutants. Modification treatment for zeolite can greatly change surface chemistry and pore structure. The article describes various modification methods of zeolite, and introduces the removal mechanisms of common pollutants such as ammonium, phosphorus and heavy metals. In addition, this review paper intends to present feasibility of applying modified zeolite to constructed wetlands which will be beneficial to achieve higher removal effect.
Subject(s)
Phosphorus/chemistry , Wastewater/chemistry , Water Pollutants, Chemical/chemistry , Water Purification/methods , Wetlands , Zeolites/chemistryABSTRACT
BACKGROUND: Acute spinal cord injury (SCI) is one of the most common and devastating causes of sensory or motor dysfunction. Nuclear factor-kappa B(NF-κB)-mediated neuroinflammatory responses, in addition to nitric oxide (NO), are key regulatory pathways in SCI. Paeoniflorin (PF), a major active component extracted from Paeonia roots, has been suggested to exert neuroprotective effects in the central nervous system. However, whether PF could improve the motor function after SCI in vivo is still unclear. METHOD: Immunohistochemical analysis, western blot, real-time quantitative PCR, immunofluorescence staining, and histopathological and behavioral evaluation were used to explore the effects of paeoniflorin after SCI for 14 days. RESULTS: In this study, PF treatment significantly inhibited NF-κB activation and downregulated the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2(COX-2), and Nogo-A. Comparing behavioral and histological changes in SCI and PF treatment groups, we found that PF treatment improved motor function recovery, attenuated the histopathological damage, and increased neuronal survival in the SCI model. PF treatment also reduced expression levels of Bax and c-caspase-3 and increased the expression level of Bcl-2 and cell viabilities. Upregulation of TNF-α, IL-6, and IL-1ß after injury was also prevented by PF. CONCLUSION: These results suggest that the neuroprotective effects of PF are related to the inhibition of the NF-κB signaling pathway. And PF may be a therapeutic strategy in spinal cord injury.
Subject(s)
NF-kappa B/antagonists & inhibitors , Nerve Tissue Proteins/antagonists & inhibitors , Neuroprotective Agents/pharmacology , Paeonia/chemistry , Plant Extracts/pharmacology , Plant Roots/chemistry , Spinal Cord Injuries , Acute Disease , Animals , Female , Inflammation/drug therapy , Inflammation/metabolism , Inflammation/pathology , Male , NF-kappa B/metabolism , Nerve Tissue Proteins/metabolism , Neuroprotective Agents/chemistry , Plant Extracts/chemistry , Rats , Rats, Sprague-Dawley , Spinal Cord Injuries/drug therapy , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/pathologyABSTRACT
BACKGROUND: Scalp acupuncture has shown a remarkable treatment efficacy on motor dysfunction in patients with stroke in China, especially the motor area of Jiao's scalp acupuncture, which is the most widely used treatment. However, previous studies have summarized that the clinical curative effect of acupuncture treatment for stroke remains uncertain. Meanwhile, no randomized controlled trials on Jiao's scalp acupuncture have been performed. The aim of this study is to evaluate the efficacy and safety of Jiao's scalp acupuncture for motor dysfunction in ischemic stroke. METHODS/DESIGN: This is an assessor- and analyst-blinded, randomized controlled trial. One hundred and eight stroke patients with motor dysfunction meeting the inclusion criteria will be allocated by a 1:1 ratio into either an acupuncture treatment group or a control group. Stroke patients in the control group will receive conventional rehabilitation treatment, whereas a combination of Jiao's scalp acupuncture and conventional rehabilitation treatment will be applied to the acupuncture group. Forty treatment sessions will be performed over an 8-week period. The Fugl-Meyer Assessment scale will be assessed as the primary outcome measure. The Modified Barthel Index, the Stroke-Specific Quality of Life, and the Stroke Syndrome of Traditional Chinese Medicine scales will be selected as secondary outcome measurements. All assessments will be conducted at baseline, week 4 (treatment 20), week 8 (treatment 40), week 12 (follow-up), and week 16 (follow-up). DISCUSSION: This is the first trial evaluating the efficacy and safety of Jiao's scalp acupuncture for motor dysfunction in ischemic stroke. The results of this trial are expected to provide relevant evidence demonstrating that Jiao's scalp acupuncture can be used as an effective rehabilitation treatment method for improving motor dysfunction in ischemic stroke. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02871453 . Registered on 17 July 2016.
Subject(s)
Acupuncture Therapy/methods , Brain Ischemia/therapy , Motor Activity , Motor Cortex/physiopathology , Stroke Rehabilitation/methods , Stroke/therapy , Acupuncture Points , Acupuncture Therapy/adverse effects , Adult , Aged , Brain Ischemia/diagnosis , Brain Ischemia/physiopathology , China , Clinical Protocols , Disability Evaluation , Female , Humans , Male , Middle Aged , Quality of Life , Recovery of Function , Research Design , Scalp , Stroke/diagnosis , Stroke/physiopathology , Stroke Rehabilitation/adverse effects , Surveys and Questionnaires , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: Bone marrow mesenchymal stem cells sometimes improve symptoms of inflammatory bowel disease. AIM: To test the effects of combined granulocyte colony-stimulating factor (G-CSF) and MSC therapy in a rat model of ulcerative colitis (UC). METHODS: Seventy-two rats with TNBS-induced UC were divided into control or treatment groups: control (no disease and no treatment), no treatment (model), 5-aminosalicylate (5-ASA) enema, or MSCs (labeled with BrdU) with (MSC/GCSF) or without (MSC) G-CSF, and G-CSF alone (GCSF). On days 14 and 28 post-treatment, macroscopic and histological appearances were assessed and the disease activity index (DAI) scored to evaluate the severity of disease. BrdU-labeled MSCs were identified by immunofluorescence to confirm transplantation and their location. The inflammatory profile of each group was evaluated by measuring expression of nuclear NF-κB p65, serum TNF-α, and IL-10 and by activity of mucosal myeloperoxidase (MPO). RESULTS: Rats receiving MSC and G-CSF combination therapy had increased recruitment of MSCs to the colonic mucosa compared with rats receiving MSC transplantation alone. On day 28, the DAI, MPO activity, serum TNF-α and IL-10 levels, and NF-κB p65 expression in the combination therapy group were significantly lower compared to animals receiving no treatment, MSCs alone, or G-CSF alone (P < 0.05). CONCLUSION: Intravenously transplanted MSCs migrate and distribute to the colon to effectively alleviate the symptoms of UC, while G-CSF enhances this effect via an anti-inflammatory effect and improvement in the pathologic features of UC. G-CSF may be a promising therapeutic regulator of MSCs that can improve therapeutic outcomes in patients with UC.
Subject(s)
Colitis, Ulcerative/therapy , Granulocyte Colony-Stimulating Factor/pharmacology , Mesenchymal Stem Cell Transplantation , Animals , Colitis, Ulcerative/chemically induced , Gene Expression Regulation , Inflammation/metabolism , Inflammation/pathology , Mesalamine/therapeutic use , Mesenchymal Stem Cells/physiology , Rats , Severity of Illness Index , Trinitrobenzenesulfonic Acid/toxicityABSTRACT
OBJECTIVE: To study the effect of PP333 treatment on seed yield,medicinal materials yield and quality of Flemingia Philippinensis. METHODS: The experiment was in split plot design for PP333 in main plot and in planting density subplot. RESULTS: The seed yield of 600 mg/L (PP333) + 60 plants/m2 (planting density) was the highest. The medicinal materials yield of 600 mg/L (PP333) + 90 plants/m2 (planting density) was the highest. The quality of 900 mg/L( PP333) + 60 plants/m2 (planting density) was the best. CONCLUSION: The appropriate density of PP333 and planting can improve seed yield,medicinal materials yield and quality of Flemingia Philippinensis.
Subject(s)
Biomass , Fabaceae/growth & development , Plant Growth Regulators/pharmacology , Plants, Medicinal/growth & development , Seeds , Agriculture/methods , Fabaceae/chemistry , Flavonoids/analysis , Plant Roots/chemistry , Plants, Medicinal/chemistry , Quality ControlABSTRACT
The red raspberry extract possesses potent antioxidant capacity and anticancerous activity in vitro and in vivo. The objective of this study was to determine whether red raspberry extract affected the cell cycle, angiogenesis, and apoptosis in hepatic lesion tissues from a rat model induced by diethylnitrosamine (DEN) as well as changes of serum proteomics. Rats were treated with red raspberry extract (0.75, 1.5, or 3.0 g/kg of body weight) by gavage starting 2 h after DEN administration and continued for 20 wk. Red raspberry extract inhibited cell proliferation, vascular endothelial growth factor VEGF expression, and induced apoptosis in the hepatic lesion tissues. In addition, 2 protein peaks (2597.93 and 4513.88 m/z) were identified to differentially express in the 3.0 g/kg body weight and positive control groups by serum proteomics. These results suggest that a dietary supplement with red raspberry effectively protects against chemically induced hepatic lesions in rats.
Subject(s)
Apoptosis/drug effects , Cell Proliferation/drug effects , Fruit/chemistry , Plant Extracts/pharmacology , Rosaceae/chemistry , Animals , Antioxidants/pharmacology , In Situ Nick-End Labeling/methods , Male , Proteomics/methods , Rats , Rats, Wistar , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/metabolismABSTRACT
A vaccine derived from the outer membrane proteins of the Gram-negative bacterium Pseudomonas aeruginosa has been shown to have immune modulatory properties. An inactivated mutant strain of P. aeruginosa with mannose sensitive hemagglutinin fimbria (PA-MSHA) has been used for adjuvant therapy for malignant cancer. In this study, the growth of human hepatocellular carcinoma Hep G2 and BEL-7402 cells is inhibited by PA-MSHA, but not by mannose-cleaved PA-MSHA. PA-MSHA-treated cells arrested in the S phase of the cell cycle and underwent apoptosis. We hypothesize that apoptosis induced by treatment of Hep G2 and BEL-7402 cells with PA-MSHA is mediated by the mannose residues of PA-MSHA and is propagated through the extrinsic apoptosis pathway directly through caspase-8. These data provide mechanistic details for the potential application of PA-MSHA-based treatment of hepatocellular carcinoma.
Subject(s)
Apoptosis/drug effects , Bacterial Vaccines/immunology , Carcinoma, Hepatocellular/immunology , Fimbriae Proteins/immunology , Hemagglutinins/immunology , Liver Neoplasms/immunology , Mannose/pharmacology , Pseudomonas aeruginosa/immunology , Carcinoma, Hepatocellular/pathology , Cell Cycle , Flow Cytometry , Humans , Immunologic Factors/immunology , In Situ Nick-End Labeling , Liver Neoplasms/pathology , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, CulturedABSTRACT
Our previous studies have shown that central administration of angiotensin (ANG II) causes arginine vasopressin (AVP) release in the fetus at 70-90% gestation. This is evidence that the hypothalamic-neurohypophysial system is relatively mature before birth. However, few data exist regarding central ANG receptor mechanisms-mediated AVP response during fetal life. To determine roles of brain ANG receptor subtypes in this response, AT1 and AT2 receptor antagonists, losartan and PD123319, were investigated in the brain in chronically prepared ovine fetuses at the last third of gestation. Application of losartan intracerebroventricularly (i.c.v.) at 0.5 mg/kg suppressed central ANG II-stimulated plasma AVP release. Losartan at 5 mg/kg (i.c.v.) demonstrated a significant enhancement of AVP increase to i.c.v. ANG II. Associated with the increase of plasma vasopressin levels, c-fos expression in the hypothalamic neurons was significantly different between the low and high doses of losartan. The low dose losartan markedly reduced the dual immunoreactivity for FOS and AVP in the supraoptic nuclei and paraventricular nuclei after i.c.v. ANG II, whereas the high dose losartan together with ANG II, significantly increased the co-localization of positive FOS in the AVP-containing neurons than that induced by i.c.v. ANG II alone. Central ANG II induced fetal plasma vasopressin increase was not altered by PD123319. The data suggest that losartan in the fetal brain has remarkably different effects based on the doses administrated on central ANG II-related neuroendocrine effects at the late gestation, and that the AT1 mechanism is critical in the regulation of fetal body fluid homeostasis related to plasma AVP levels.
Subject(s)
Angiotensin II/antagonists & inhibitors , Arginine Vasopressin/blood , Fetus/metabolism , Hypothalamus/metabolism , Losartan/pharmacology , Proto-Oncogene Proteins c-fos/metabolism , Vasopressins/metabolism , Animals , Arginine Vasopressin/metabolism , Female , Fetus/cytology , Hypothalamus/cytology , Hypothalamus/drug effects , Imidazoles/metabolism , Imidazoles/pharmacology , Injections, Intraventricular , Losartan/administration & dosage , Pregnancy , Pyridines/metabolism , Pyridines/pharmacology , Sheep , Time FactorsABSTRACT
The renin-angiotensin system plays an important role in cardiovascular control. Intracerebroventricular (i.c.v.) angiotensin (ANG) II causes a reliable pressor response in the fetus at 90% gestation. To determine the roles of brain AT1 and AT2 receptors in this response, the effects of the central AT1 and AT2 receptor antagonists losartan and PD123319 were investigated in chronically prepared near-term ovine fetuses. Losartan at 0.5 mg/kg (i.c.v.) abolished central ANG II-induced pressor responses. High-dose losartan (5 mg/kg, i.c.v.) showed a potentiation of the pressor response to i.c.v. ANG II, accompanied by bradycardia. Associated with the pressor responses, c-fos expression in the cardiovascular controlling areas was significantly different between the low and high doses of losartan. These areas included the subfornical organ, median preoptic nucleus, organum vasculosum of the lamina terminalis, and paraventricular nuclei in the forebrain, and the tractus solitarius nuclei, lateral parabrachial nuclei in the hindbrain. Low-dose losartan markedly reduced c-fos in these areas after i.c.v. ANG II, while the high-dose losartan together with ANG II elicited a much stronger FOS-immunoreactivity in these areas than that induced by i.c.v. ANG II alone. This is a novel finding, that c-fos expression in the brain can be both activated and inhibited under the same condition. Central ANG II-induced fetal pressor responses were not altered by PD123319 (0.8 mg/kg). These results indicate that i.c.v. losartan at a high and a low dose has strikingly different effects on central ANG II-induced pressor responses in fetuses at late gestation, and that the AT1 mechanism plays an important role in fetal cardiovascular regulation.
Subject(s)
Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin II/drug effects , Genes, fos/drug effects , Losartan/administration & dosage , Prosencephalon/drug effects , Analysis of Variance , Angiotensin II/administration & dosage , Angiotensin II/metabolism , Animals , Blood Pressure/drug effects , Cardiovascular System/drug effects , Cardiovascular System/embryology , Cardiovascular System/metabolism , Dose-Response Relationship, Drug , Female , Fetus/drug effects , Genes, fos/physiology , Gestational Age , Homeostasis/drug effects , Homeostasis/physiology , Injections, Intraventricular , Pregnancy , Prosencephalon/embryology , Prosencephalon/metabolism , Sheep , Statistics, NonparametricABSTRACT
The central renin-angiotensin system is important in the control of blood pressure in the adult. However, few data exist about the in utero development of central angiotensin-mediated pressor responses. Our recent studies have shown that the application of ANG II into the fetal brain can increase blood pressure at near term. The present study determined fetal blood pressure and heart rate in response to a central application of ANG II in the chronically prepared preterm ovine fetus, determined the action sites marked by c-Fos expression in the fetal central pathways after intracerebroventricular injection of ANG II in utero, and determined angiotensin subtype 1 receptors in the fetal hypothalamus. Central injection of ANG II significantly increased fetal mean arterial pressure (MAP). Adjusted fetal MAP against amniotic pressure was also increased by ANG II. Fetal heart rate was subsequently decreased after the central administration of ANG II and/or the increase of blood pressure. ANG II induced c-Fos expression in the central putative cardiovascular area, the paraventricular nuclei in the brain sympathetic pathway. Application of ANG II also caused intense Fos immunoreactivity in the tractus solitarius nuclei in the hindbrain. In addition, intense angiotensin subtype 1 receptors were expressed in the hypothalamus at preterm. These data demonstrate that central ANG II-related pressor centers start to function as early as at preterm and suggest that the central angiotensin-related sympathetic pathway is likely intact in the control of blood pressure in utero.
Subject(s)
Angiotensin II/pharmacology , Blood Pressure/drug effects , Fetus/physiology , Hypothalamus/drug effects , Neurons/drug effects , Receptors, Angiotensin/metabolism , Vasoconstrictor Agents/pharmacology , Angiotensin II/administration & dosage , Animals , Female , Genes, fos/genetics , Heart Rate, Fetal/drug effects , Hemodynamics/physiology , Immunohistochemistry , Injections, Intraventricular , Neural Pathways/embryology , Neural Pathways/physiology , Pregnancy , Renin-Angiotensin System/physiology , Sheep , Vasoconstrictor Agents/administration & dosageABSTRACT
Central renin-angiotensin system (RAS) is as important as the peripheral RAS in the control of the cardiovascular homeostasis in the adult. However, previous fetal studies on angiotensin II (ANG II)-induced cardiovascular responses focused exclusively on the peripheral side. Thus, few data exist characterizing the in utero development of central angiotensin-mediated pressor responses. The present study determined cardiovascular responses to central application of ANG II in the chronically prepared near-term ovine fetus, and determined the action sites marked by c-fos expression in the fetal hypothalamus following intracerebroventricular (icv) injection of ANG II in utero. ANG II significantly increased fetal systolic, diastolic, and mean arterial pressure (MAP) within 5 min after injection of this peptide into the brain. Adjusted fetal MAP against amniotic pressure was also increased by icv ANG II, associated with increased c-fos in the central putative cardiovascular area--the paraventricular nuclei (PVN). Application of ANG II also induced intense c-fos expression in the supraoptic nuclei (SON), accompanied by a significant increase of fetal plasma vasopressin (AVP) levels, while maternal blood pressure (BP) and plasma AVP concentration were not changed. These results indicate that the central ANG II-mediated pressor response is functional at the last third of gestation, acting at the sites consistent with the cardiovascular neural network in the hypothalamus.